Lower riskDrug recall · FDA · Published July 10, 2024
Endo Clonazepam Tablets Recalled Due to Labeling Error
Endo Pharmaceuticals recalls Clonazepam orally disintegrating tablets with incorrect strength labeling. Some cartons listed 0.125mg instead of 0.25mg, but tablets inside are correct. Consumers should check their product.
Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled as 0.125 mg instead of 0.25 mg. The blister strips inside the product carton reflect the correct strength of 0.25 mg.
Take action
Contact the company
📍Recalling firmEndo Pharmaceuticals, Inc.1400 Atwater Dr · Malvern, PA 19355-8701
✎ GovInfoNow plain-language explainer
Endo Pharmaceuticals is recalling Clonazepam orally disintegrating tablets that were incorrectly labeled as 0.125mg instead of 0.25mg. This labeling error could lead to incorrect dosing if the product is used without checking the actual strength. Read more at govinfonow.com/recall/32590-endo-clonazepam-tablets-recalled-due-to-labeling-error.
“Endo Clonazepam Tablets Recalled Due to Labeling Error.” GovInfoNow, updated September 23, 2026. https://govinfonow.com/recall/32590-endo-clonazepam-tablets-recalled-due-to-labeling-error. Based on FDA recall #D-0622-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0622-2024%22&limit=1).
The FDA announced on July 10, 2024, that Endo Pharmaceuticals is recalling Clonazepam Orally Disintegrating Tablets due to a labeling error where some cartons were incorrectly labeled as 0.125 mg instead of the correct 0.25 mg strength. This Class I recall affects 8,139 cartons distributed nationwide.
Distribution: Nationwide in the USA and Puerto Rico
The hazard
The hazard is a labeling error where some cartons were incorrectly labeled as 0.125 mg instead of 0.25 mg. The blister strips inside the product carton reflect the correct strength of 0.25 mg.
Context
GovInfoNow's records show Endo Pharmaceuticals has four other recalls on record since May 7, 2012. Other recent recalls of similar products include Annora Pharma Lacosamide Tablets Recall (June 4, 2026), Slate Run Recalls Eptifibatide Injection Due to Labeling Error (Feb. 12, 2026), and Inventia Chlorthalidone Recall (Sept. 3, 2026).
How to tell if you have this one
Check for the product name 'Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.125mg' on the carton. The actual tablets inside are 0.25mg, but the carton may incorrectly state 0.125mg.
Brand
Endo Pharmaceuticals
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Label
Look for the carton label stating 0.125mg instead of 0.25mg. The tablets inside are correctly labeled as 0.25mg.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 14 months after the firm started it.
1Firm started the recall
2FDA classified it Class I
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0622-2024 (July 10, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0622-2024 to see it in context.
Plain-language summary written by qwen3:4b on September 23, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.